ストックスクリーナーアプリを入手
1.49
25.13%
-0.50
アフターアワーズ：
1.47
-0.02
-1.34%
前日終値:
$1.99
開ける：
$1.865
24時間の取引高:
4.38M
Relative Volume:
2.68
時価総額：
$2.16M
収益：
$12.99M
当期純損益:
$-23.72M
株価収益率:
-0.0153
EPS:
-97.2514
ネットキャッシュフロー:
$-23.28M
1週間 パフォーマンス:
+33.04%
1か月 パフォーマンス:
-49.49%
6か月 パフォーマンス:
-76.19%
1年 パフォーマンス:
-98.83%
1日の値動き範囲:
$1.23
$1.93
1週間の範囲:
$0.9423
$3.61
52週間の値動き範囲:
$0.9423
$180.19
Aptevo Therapeutics Inc Stock (APVO) Company Profile
APVO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
APVO
Aptevo Therapeutics Inc
|
1.49 | 2.16M | 12.99M | -23.72M | -23.28M | -97.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 65.79B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 35.18B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 32.67B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2018-11-05 | 開始されました | Ladenburg Thalmann | Buy |
| 2017-10-05 | 再開されました | Piper Jaffray | Overweight |
Aptevo Therapeutics Inc (APVO) 最新ニュース
Aptevo Therapeutics Announces the Closing of $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules - ACCESS Newswire
Aptevo Secures Fresh $2.1M Capital: What This Means for Clinical Pipeline - Stock Titan
SEC Form 424B4 filed by Aptevo Therapeutics Inc. - Quantisnow
Aptevo (APVO) Sees Significant Market Rally After Equity Offering - Stocks Telegraph
Strategic Moves Drive Stock Gains For OSR, Lianhe Sowell, And Aptevo - Finimize
Aptevo Stock Rises On $2.1M Registered Direct Offering, Warrant Sale: Retail Sentiment Touches Year-High - MSN
11 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Aptevo Therapeutics Launches $2.1 Million Registered Direct Offering; Shares Rise - MarketScreener
Aptevo Therapeutics (APVO) Announces $2.1 Million Securities Off - GuruFocus
Aptevo Therapeutics announces registered direct offering and warrants sale - Investing.com
Aptevo Therapeutics prices 1.76M shares at $1.19 in registered direct offering - TipRanks
Aptevo Raises Fresh Capital: $2.1M Direct Offering Plus Warrant Restructuring - Stock Titan
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Why Penguin Solutions Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
APVO stock plunges to 52-week low, touches $0.99 - Investing.com India
APVO stock plunges to 52-week low, touches $0.99 By Investing.com - Investing.com UK
Virtu Financial LLC Has $93,000 Stake in Aptevo Therapeutics Inc. (NASDAQ:APVO) - Defense World
Aptevo Therapeutics Inc. (NASDAQ:APVO) Sees Significant Growth in Short Interest - Defense World
APVO stock plunges to 52-week low, touches $2.32 - Investing.com India
APVO stock plunges to 52-week low, touches $2.32 By Investing.com - Investing.com UK
Aptevo Therapeutics Says Two Additional Patients In Early-Stage Leukemia Trial Achieve Remission Within 30 Days of Treatment - Benzinga
Aptevo Therapeutics Reports 2 More Remissions in AML Trial -March 20, 2025 at 09:35 am EDT - Marketscreener.com
Aptevo Therapeutics Achieves Remission Success in AML Trial - TipRanks
Aptevo reports two additional AML patients achieve remission in RAINIER trial - TipRanks
Breakthrough: New AML Drug Shows 90% Success Rate, Outperforming Standard Therapy by 24% - StockTitan
Aptevo Therapeutics advances cancer antibody APVO603 in preclinical phase - Investing.com
Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy - ACCESS Newswire
Breakthrough Cancer Drug APVO603 Targets Two Immune Pathways to Fight Solid Tumors - Stock Titan
Aptevo Therapeutics (NASDAQ:APVO) Raised to Sell at StockNews.com - Defense World
Aptevo Therapeutics Inc. (NASDAQ:APVO) Sees Significant Increase in Short Interest - Defense World
APVO stock plunges to 52-week low of $2.48 amid steep annual decline - Investing.com Australia
APVO stock plunges to 52-week low of $2.48 amid steep annual decline By Investing.com - Investing.com South Africa
Aptevo Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:APVO - Benzinga
Aptevo to Participate in March Conferences - ACCESS Newswire
Can These Two Major Biotech Conferences Unlock Aptevo's Next Growth Phase? - StockTitan
APVO stock plunges to 52-week low, touches $3 mark By Investing.com - Investing.com Australia
APVO stock plunges to 52-week low, touches $3 mark - Investing.com
Aptevo Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights - ACCESS Newswire
Aptevo Therapeutics Inc. (NASDAQ:APVO) Short Interest Update - Defense World
Aptevo Therapeutics (APVO) Projected to Post Quarterly Earnings on Tuesday - Defense World
Aptevo Therapeutics Announces Poster Presentation at the 64th American Society of Hematology Annual Meeting and Exposition - ACCESS Newswire
Roth Capital Brokers Decrease Earnings Estimates for APVO - Defense World
FY2029 Earnings Estimate for APVO Issued By Roth Capital - Defense World
Aptevo Therapeutics files $100M mixed securities shelf - MSN
Aptevo Therapeutics Inc (APVO) 財務データ
収益
当期純利益
現金流量
EPS
10.70%
大文字化:
|
ボリューム (24 時間):